ASX Announcements

Jun 2021
Jun 24th, 2021
Starpharma to present at Virtual Life Sciences Investor Forum
Jun 21st, 2021
VIRALEZE UK update
Jun 18th, 2021
VIRALEZE SPL7013 virucidal against multiple COVID variants
Jun 11th, 2021
VIRALEZE antiviral nasal spray registered for sale in India
Jun 1st, 2021
VIRALEZE SPL7013 highly active in UK variant of coronavirus

May 2021
May 11th, 2021
VIRALEZE™ partners with Harlequins in the UK
May 6th, 2021
VIRALEZE™ launches in Europe

Apr 2021
Apr 28th, 2021
Shareholder Newsletter
Apr 27th, 2021
Quarterly Cashflow and Activities Report
Apr 9th, 2021
Appendix 2A

Mar 2021
Mar 30th, 2021
VIRALEZE™ now launched by LloydsPharmacy in the UK
Mar 25th, 2021
VIRALEZE™ to be launched with LloydsPharmacy in the UK
Mar 16th, 2021
DEP® HER2-lutetium outperforms in human breast cancer model
Mar 3rd, 2021
SPL7013 active against other pandemic coronaviruses

Feb 2021
Feb 25th, 2021
Interim Report and Half-Year Financial Results
Feb 23rd, 2021
VIRALEZE™ antiviral nasal spray registered in Europe
Feb 12th, 2021
Starpharma signs DEP® ADC Research Agreement with MSD
Feb 9th, 2021
AZD0466 clinical DEP® program global expansion
Feb 3rd, 2021
Change in substantial holding

Jan 2021
Jan 29th, 2021
Quarterly Cashflow and Activities Report
Jan 27th, 2021
Appendix 2A
Jan 18th, 2021
Change in substantial holding
Jan 18th, 2021
Change in substantial holding

Dec 2020
Dec 24th, 2020
Change in substantial holding
Dec 22nd, 2020
VIRALEZE COVID-19 nasal spray study to commence in January
Dec 22nd, 2020
Change in substantial holding
Dec 10th, 2020
VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21

Nov 2020
Nov 24th, 2020
Change in Director's Interest Notice - J Fairley
Nov 24th, 2020
Appendix 3G
Nov 20th, 2020
2020 AGM Results
Nov 20th, 2020
Retirement of non-executive director Richard Hazleton
Nov 20th, 2020
AGM Chairman address and CEO presentation
Nov 19th, 2020
SPL7013 shows potent antiviral activity in RSV
Nov 13th, 2020
Appendix 3G
Nov 4th, 2020
Change in Director's Interest Notice - R Thomas
Nov 4th, 2020
Change in Director's Interest Notice - J Fairley
Nov 4th, 2020
Change in Director's Interest Notice - P Turvey
Nov 4th, 2020
Appendix 2A

Oct 2020
Oct 30th, 2020
Appendix 2A
Oct 30th, 2020
Quarterly Cashflow and Activities Report
Oct 29th, 2020
Completion of Placement and SPP raises $48.9M in total
Oct 21st, 2020
Starpharma receives $5.7M R&D tax incentive refund
Oct 20th, 2020
Shareholder Update October 2020
Oct 19th, 2020
Notice of Annual General Meeting/Proxy Form
Oct 9th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 7th, 2020
Share Purchase Plan offer document
Oct 6th, 2020
Appendix 2A
Oct 6th, 2020
Cleansing Notice
Oct 5th, 2020
Change in Director's Interest Notice - R Thomas
Oct 5th, 2020
Change in Director's Interest Notice - J Fairley

Sep 2020
Sep 30th, 2020
Investor Presentation
Sep 30th, 2020
Starpharma completes oversubscribed A$45M placement
Sep 30th, 2020
Proposed issue of Securities
Sep 28th, 2020
Trading halt
Sep 25th, 2020
VivaGel® BV secures TGA approval for prevention of BV
Sep 23rd, 2020
2020 Annual General Meeting
Sep 23rd, 2020
Appendix 2A
Sep 18th, 2020
Change in substantial holding
Sep 17th, 2020
Change in substantial holding
Sep 17th, 2020
Starpharma to present at OTCQX Life Sciences Investor Forum
Sep 14th, 2020
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Sep 3rd, 2020
Change in substantial holding
Sep 3rd, 2020
Starpharma awarded $1M MRFF funding for COVID-19 spray
Sep 1st, 2020
SPL creates slow release soluble DEP® remdesivir nanoparticle
Sep 1st, 2020
Change in substantial holding

Aug 2020
Aug 27th, 2020
Annual report and full year financial results
Aug 27th, 2020
Appendix 4G - Corporate Governance Statement
Aug 25th, 2020
SPL7013 nasal spray for COVID-19 – development update
Aug 17th, 2020
Starpharma signs new DEP® partnership with Chase Sun

Jul 2020
Jul 30th, 2020
DEP® docetaxel and gemcitabine combination trial commences
Jul 30th, 2020
Quarterly Cashflow and Activities Report
Jul 27th, 2020
AZD0466 trial opens MD Anderson Cancer Center as a site
Jul 9th, 2020
New Australian site opening for DEP® trials

Jun 2020
Jun 29th, 2020
DEP® irinotecan boosts immuno-oncology in colon cancer models
Jun 23rd, 2020
Multiple DEP® products showcased at AACR 2020
Jun 18th, 2020
Starpharma to present at OTCQX Virtual Investor Conference
Jun 17th, 2020
DEP® lutetium effective in human prostate cancer model
Jun 16th, 2020
VivaGel® BV launched in central and eastern European countries
Jun 16th, 2020
Notice of initial substantial holder

May 2020
May 26th, 2020
Notice of initial substantial holder
May 14th, 2020
Shareholder Update May 2020
May 7th, 2020
DEP® irinotecan phase 2 commences after positive phase 1 results
May 5th, 2020
Starpharma presents at Macquarie Australia Conference

Apr 2020
Apr 15th, 2020
SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)
Apr 7th, 2020
Quarterly Cashflow and Activity Report

Mar 2020
Mar 20th, 2020
Appendix 2A
Mar 4th, 2020
Okamoto licenses VivaGel® antiviral condom in Asian countries
Mar 2nd, 2020
Starpharma appoints David McIntyre and Appendix 3X

Feb 2020
Feb 24th, 2020
Interim Report and Half-Year Financial Results
Feb 13th, 2020
VivaGel BV launched in Asia
Feb 12th, 2020
David McIntyre appointed as non-executive director
Feb 11th, 2020
Starpharma receives US$3M milestone from AstraZeneca

Jan 2020
Jan 30th, 2020
Shareholder Update January 2020
Jan 29th, 2020
Quarterly Cashflow Report
Jan 24th, 2020
Appendix 3B